Medtronic plc has received CE Mark for the Visia AF™ and Visia AF MRI™ SureScan® single-chamber implantable cardioverter defibrillators (ICDs), which can detect and monitor new onset, asymptomatic, and previously undiagnosed atrial fibrillation (AF).
An estimated 33 million people worldwide have AF, making it the most common cardiac rhythm disorder. Early detection of AF can help a physician better tailor treatment to the needs of the patient, which is where Medtronic’s new ICD fits in. The Visia AF devices include a proprietary algorithm that accurately detects AF episodes, captures AF burden frequency and duration, and alerts the physician from the patient’s home.
The Visia AF ICDs build on the proven performance of the Medtronic Evera(TM) family of ICDs, and feature a contoured shape with thin, smooth edges that increases patient comfort by reducing skin pressure by 30 percent, says the company.
“Medtronic is committed to continuing to develop a wide range of technologies to help patients with AF,” said Marshall Stanton, M.D., vice president and general manager of the Tachycardia business, which is part of the Cardiac Rhythm and Heart Failure division at Medtronic. “With devices like the Visia AF ICDs and the Reveal LINQ(TM) Insertable Cardiac Monitor, which detects and monitors abnormal heart rhythms for up to three years, we aim to increase AF detection and enable physicians to manage a patient’s risk for strokes and heart failure.”
Source: Medtronic, plc